Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma (AHOD0831)

This collection contains data from the Children’s Oncology Group (COG) Clinical Trial NCT01026220, “Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma". Principle Investigator: Kara Kelly, MD (pediatric oncologist and the Chair of Roswell Park Oishei Children’s Cancer and Blood Disorders Program, Buffalo, NY.). This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma. Therapeutic agents used on trial include 1 or more of the following: Biological: bleomycin sulfate; Drug: doxorubicin hydrochloride; Drug: liposomal vincristine sulfate; Drug: vinorelbine tartrate; Drug: cyclophosphamide; Drug: etoposide phosphate; Drug: prednisone; Biological: filgrastimDrug: ifosfamide.

本数据集收录来自儿童肿瘤学组（Children’s Oncology Group, COG）编号为NCT01026220的临床试验数据，试验名称为“联合化疗与放射治疗治疗新诊断霍奇金淋巴瘤的年轻患者”。本试验的首席研究员为卡拉·凯利（Kara Kelly）医学博士，其同时担任纽约州布法罗市罗斯韦尔公园奥伊谢儿童癌症与血液疾病项目主任，为儿科肿瘤学家。此项III期临床试验旨在评估联合化疗与放射治疗方案用于治疗新诊断霍奇金淋巴瘤年轻患者的临床疗效。本试验所使用的治疗制剂包括以下一种或多种：生物制剂：博来霉素硫酸盐（bleomycin sulfate）；药物：盐酸多柔比星（doxorubicin hydrochloride）；药物：硫酸脂质体长春新碱（liposomal vincristine sulfate）；药物：酒石酸长春瑞滨（vinorelbine tartrate）；药物：环磷酰胺（cyclophosphamide）；药物：依托泊苷磷酸盐（etoposide phosphate）；药物：泼尼松（prednisone）；生物制剂：非格司亭（filgrastim）；药物：异环磷酰胺（ifosfamide）。